Celgene’s Otezla Grabs New Psoriatic Arthritis Patients As Launch Accelerates
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene reports its apremilast is attracting more new psoriatic arthritis patients than branded leaders in the space. Sales for its first full quarter amounted to $18 million and new indication in psoriasis should start to contribute later this year, company says.
You may also be interested in...
Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label
Celgene estimates 80% of moderate-to-severe plaque psoriasis patients experience the disease in their scalps, meaning positive data in this indication could broaden the market opportunity for Otezla substantially. Novartis’ Cosentyx got scalp psoriasis added to its US label in February.
Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline
The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.
Celgene Dips Into The Antibody Well Once More, Partners With Sutro
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.